Write in a clean editor, then format for JAAD Case Reports in one click — DocuGuru applies the official Elsevier template with numbered references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
JAAD Case Reports is a peer-reviewed journal published by Elsevier, covering Autoimmune Bullous Skin Diseases, Cutaneous lymphoproliferative disorders research, Cancer and Skin Lesions.
| Publisher | Elsevier |
|---|---|
| Reference style | Numbered (Elsevier) Numbered — [1], [2] in the text [1] A. Smith, B. Jones, C. Lee, A representative article title, JAAD Case Reports 12 (2023) 45–58.
Formats any DOI in JAAD Case Reports style. No sign-up. |
| Publishes research in | Autoimmune Bullous Skin Diseases Cutaneous lymphoproliferative disorders research Cancer and Skin Lesions Autoimmune and Inflammatory Disorders Genetic and rare skin diseases. |
| ISSN | 2352-5126 |
| Citation impact (2-yr) | 0.74 |
| h-index | 44 |
| i10-index | 703 |
| Total citations | 23,394 |
| Article processing charge | $600 |
| Open access | Yes |
| Top institutions publishing here | Harvard University |
| Journal website | www.journals.elsevier.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
Until now, the skin findings reported in association with coronavirus disease 2019 (COVID-19) infection remain sparse, nonspecific, and devoid of any prognostic significance.1,2 This case report emphasizes a novel cutaneous sign of utmost importance for dermatologists to recognize.
A few months ago, we reported that to consider vesicular exanthems associated with COVID-19, varicella-zoster virus (VZV) and herpes simplex virus must be ruled out.1 The natural history of herpes zoster is influenced by the immune status of the host. Reactivation is influenced by age-related immunosenescence, disease-related immunocompromised state, or iatrogenic immunosuppression, with age being…
Immune checkpoint inhibitors show remarkable antitumor activity across multiple tumor types, with approval of programmed death–1 (PD-1) inhibitors for non–small cell lung cancer and melanoma. A recent clinical trial found median progression-free survival of 11.5 months for combined nivolumab plus ipilimumab therapy for metastatic melanoma compared with 6.9 months (nivolumab alone) or 2.9 months (ipilimumab…
Pembrolizumab is a humanized antibody that targets the programmed cell death-1 (PD-1) receptor. It is currently approved by the US Food and Drug Administration for patients with advanced melanoma and metastatic non–small cell lung cancer. As an immune checkpoint inhibitor, pembrolizumab augments a patient's immune system against an underlying malignancy.
Coronavirus disease 2019 (COVID-19) is causing a rapidly expanding pandemic. The Centers for Disease Control and Prevention's website describes fever, cough, and shortness of breath as the primary symptoms of the disease, but it does not describe cutaneous manifestations of the illness. Understanding how COVID-19 might present on the skin may help practitioners and patients…
